J Cancer Prev.
2015 Dec;20(4):281-286. 10.15430/JCP.2015.20.4.281.
Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells
- Affiliations
-
- 1Department of Oral Biology, Oral Cancer Research Institute, BK21 PLUS Project, Yonsei University College of Dentistry, Seoul, Korea. wychung@yuhs.ac
- 2Department of Applied Life Science, Yonsei University Graduate School, Seoul, Korea.
- 3Department of Dental Hygiene, College of Science and Technology, Kyungpook National University, Sangju, Korea.
- KMID: 2380881
- DOI: http://doi.org/10.15430/JCP.2015.20.4.281
Abstract
- Bone destruction induced by the metastasis of breast cancer cells is a frequent complication that is caused by the interaction between cancer cells and bone cells. Receptor activator of nuclear factor kappa-B ligand (RANKL) and the endogenous soluble RANKL inhibitor, osteoprotegerin (OPG), directly play critical roles in the differentiation, activity, and survival of osteoclasts. In patients with bone metastases, osteoclastic bone resorption promotes the majority of skeletal-related events and propagates bone metastases. Therefore, blocking osteoclast activity and differentiation via RANKL inhibition can be a promising therapeutic approach for cancer-associated bone diseases. We investigated the potential of isoliquiritigenin (ISL), which has anti-proliferative, anti-angiogenic, and anti-invasive effects, as a preventive and therapeutic agent for breast cancer cell-induced bone destruction. ISL at non-toxicity concentrations significantly inhibited the RANKL/OPG ratio by reducing the production of RANKL and restoring OPG production to control levels in hFOB1.19 cells stimulated with conditioned medium (CM) of MDA-MB-231 cells. In addition, ISL reduced the expression of cyclooxygenase-2 in hFOB1.19 cells stimulated by CM of MDA-MB-231 cells. Therefore, ISL may have inhibitory potential on breast cancer-induced bone destruction.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cellular Localization of RANKL and RANK Production in Giant Cell Tumors of Bone and Tendon Sheath by Immunohistochemistry
- The effect of progressive tensional force on mRNA expression of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in the human periodontal ligament cell
- Expression of Osteoprotegerin and RANK Ligand in Breast Cancer Bone Metastasis
- Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
- The Relationship between Polymorphisms of Wnt Antagonists Genes and Production of Osteoprotegerin (OPG)-soluble receptor Activator of NF-kappaB Ligand (sRANKL) by Whole Blood Cells
